Phase I clinical trial of WT1 vaccination for MDS with dose escalation

Phase I clinical trial of WT1 vaccination for MDS with dose escalation - Phase I clinical trial of WT1 vaccination for MDS

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024497

Enrollment

Registered

2016-10-20

Start date

2016-10-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MDS

Interventions

Intradermal injection of WT1 peptides biweekly

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients diagnosed as MDS HLA-A2402 Elevated WT1 expression in peripheral blood or bone marrow

Exclusion criteria

Exclusion criteria: Dysfunction of major organs

Design outcomes

Primary

Measure	Time frame
Frequencies of adverse events (Grade3,4)	—

Countries

Japan

Contacts

Public ContactNaoki Hosen

Osaka University Graduate School of Medicine Cancer Stem Cell Biology

hnaoki@imed3.med.osaka-u.ac.jp0668793676

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026